Content & Learning Objectives

WEBINAR SERIES

JUST RELEASED. STILL SUPERIOR.

Key Topics

Analyze the key outcomes of the SMART Trial and determine what they mean for patients.

Understand bioprosthetic valve dysfunction (BVD), Prosthesis-patient mismatch (PPM), and thrombosis.

Outline considerations for small annuli patients (<430 mm²) and women.

How these results impact real-world pre-case planning and patient selection.

Learning Objectives

01Outline definitions and types of BVD, preventative strategies, and implications.

02Translate trial results into real-world clinical practice.

03Understand how pre-case planning, imaging, and tools can support patient selection.

04Identify indicators of low-flow, low-gradient severe aortic stenosis.

Session I

Faculty

5 Speakers

MODIsmael Ortiz Cartagena, MD

SPKHoward C. Herrmann, MD | Leonardo de Freitas Campos Guimarães, MD, PhD | Ismael Ortiz Cartagena, MD | Pablo Manuel Lamelas, MD, MSc | Benjamin R. Stripe, MD

Program Agenda

76 MIN8 ITEMS

INTRO

TALK

CASE

DISCUSS

DATA

Q&A

Session Timeline76 min total

6:00 PM7:16 PM

6:00 PM5 min

Welcome & Introduction

Ismael Ortiz Cartagena, MD

6:05 PM15 min

SMART Trial 3-Year Results

Howard C. Herrmann, MD

6:20 PM10 min

Discussion

All Faculty

6:30 PM12 min

Case from Practice

Leonardo de Freitas Campos Guimarães, MD, PhD

6:42 PM12 min

Case from Practice

Pablo Manuel Lamelas, MD, MSc

6:54 PM12 min

Case from Practice

Benjamin R. Stripe, MD

7:06 PM10 min

Discussion

All Faculty

7:16 PM

Live Q&A and Panel

All Faculty

1x INTRO

1x DATA

2x DISCUSS

3x CASE

1x Q&A

CLICK ROW TO EXPAND

Registration

LIVE SERIES

36days

Next sessionSession IJun 15, 2026 · 23:00 ESTLive audio translation to Spanish & Portuguese

On Demand Materials

THE FUTURE OF TAVR

S3 on Evolut

Harold Dauerman, MD

Evolut on S3

Suahil Allaqaband, MD

Evolut in Evolut

Jaffar Khan, MD

Evolut in Sapien

Elizabeth Grier, MD

PDF

Redo TAV Case Planning

PDF Resource

Support

CONTACT

Still have questions?

Send us a message and we'll get back to you.

The Future of TAVR:3-Year SMART Trial Results